Results 61 to 70 of about 737 (141)

Data_Sheet_1_Phase III, randomized, double-blind, placebo-controlled clinical study: a study on the safety and clinical efficacy of AZVUDINE in moderate COVID-19 patients.PDF [PDF]

, 2023
BackgroundIn 2019, a highly pathogenic coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) surfaced and resulted in the outbreak of coronavirus disease 2019 (COVID-19).
Pingsheng Lei (5240192), Aline dos Santos Moreira (17203549), Cléber Glória Silva (17203552), Paula Gebe Abreu Cabral (6515375), Renato Martins da Silva (14787250), Antônio Brazil Viana Junior (14787268), Raul Ferraz Arruda (14787253), Sávio Bastos de Souza (6700298), Arícia Leone Evangelista Monteiro de Assis (14787259), Wim Maurits Sylvain Degrave (16933380), Junbiao Chang (1523644), Sheila Passos de Figueiredo Cabral (14787256)   +11 more
core   +1 more source

Data_Sheet_2_Phase III, randomized, double-blind, placebo-controlled clinical study: a study on the safety and clinical efficacy of AZVUDINE in moderate COVID-19 patients.docx [PDF]

, 2023
BackgroundIn 2019, a highly pathogenic coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) surfaced and resulted in the outbreak of coronavirus disease 2019 (COVID-19).
Pingsheng Lei (5240192), Aline dos Santos Moreira (17203549), Cléber Glória Silva (17203552), Paula Gebe Abreu Cabral (6515375), Renato Martins da Silva (14787250), Antônio Brazil Viana Junior (14787268), Raul Ferraz Arruda (14787253), Sávio Bastos de Souza (6700298), Arícia Leone Evangelista Monteiro de Assis (14787259), Wim Maurits Sylvain Degrave (16933380), Junbiao Chang (1523644), Sheila Passos de Figueiredo Cabral (14787256)   +11 more
core   +1 more source

A Review on Medicinal Chemistry and Biological Activity of Dihydropyrimidinones Against HIV

Archiv der Pharmazie, Volume 359, Issue 4, April 2026.
This article presents the latest advances in the development of dihydropyrimidinone (DHPM) derivatives as promising candidates against HIV. By exploring their interactions with essential viral targets and highlighting innovative compounds with potent antiviral activity, we provide an updated perspective on the opportunities for new antiretroviral ...
Debora I. Leite, Fernando B. Macedo, Murilo Marinho de C. Lima, Isabelle S. Brum, Jonathan Fragoso Miranda de Oliveira, Ana Clara S. Costa, Stella C. Duarte, Sarah Moon, Stefany de Castro B. Moura, Andressa P. de Oliveira, Nubia Boechat, Monica M. Bastos   +11 more
wiley   +1 more source

Real-world efficacy of oral azvudine in hospitalized patients with COVID-19: A multicenter retrospective cohort study

Journal of Infection and Public Health
Background: Azvudine has become a widely used treatment for COVID-19 in China. Our study aimed to assess the real-world efficacy of azvudine in hospitalized COVID-19 patients during the omicron variant surge.
Rui Han, Youhong Guan, Pulin Li, Min Tang, Guanghe Fei, Daxiong Zeng, Ran Wang   +6 more
doaj   +1 more source

Pharmacokinetics and Safety of Single and Multiple Doses of Molnupiravir in Healthy Male Chinese Adults: An Open‐Label, Fixed Sequence, Phase 1 Study

Clinical and Translational Science, Volume 19, Issue 4, April 2026.
ABSTRACT Molnupiravir is an orally administered prodrug of β‐D‐N4‐hydroxycytidine (NHC) that is conditionally approved in China for the treatment of mild to moderate COVID‐19 in nonhospitalized adults at high risk of disease progression. Molnupiravir is rapidly absorbed and hydrolyzed to deliver NHC into systemic circulation.
Jixiang Zhu, Danning Zhang, Zhiping Liu, Bei Yan, Yanqiao Zang, Weiwei Zhao, Fang Sun, Brian M. Maas, Mickie H. Cheng, S. Aubrey Stoch, Haiyan Li   +10 more
wiley   +1 more source

Characteristics of patients with non-severe infections of different SARS-CoV-2 omicron subvariants in China. [PDF]

Front Med (Lausanne)
ObjectiveThe aim of this study was to explore the clinical characteristics of patients infected with different Omicron subvariants presenting non-severe disease, evaluate the safety and efficacy of Azvudine for treatment of COVID-19, in order to broaden ...
Yuan W, Liu Y, Zhan H, Wei F, Zhang Q, Gao H, Yan H, Huang T, Li Y, Dai E.   +9 more
europepmc   +3 more sources

Are Tetrapleura tetraptera Phytochemicals Druggable Against SARS‐CoV‐2 Papain‐Like Protein? A Computational Approach

New Zealand Journal of Botany, Volume 64, Issue 1, March 2026.
SARS‐CoV2 Omicron and its substrains are still a critical global health issue and extremely contagious, even with widespread vaccination efforts. Hospitalizations and mortality rates linked to these variants are still prevalent. Current therapeutic options face challenges, including low effectiveness, suboptimal pharmacokinetics, and drug resistance ...
Frank Eric Tatsing Foka, Hazel Tumelo Mufhandu   +1 more
wiley   +1 more source

Disruption of Spike Priming in Virus Entry: Tetrandrine as a Pan‐Coronavirus Inhibitor

MedComm, Volume 6, Issue 9, September 2025.
Tetrandrine inhibits the infection of HCoV‐OC43, HCoV‐229E, SARS‐CoV‐2, and its major variants by blocking virus entry. Specifically, tetrandrine breaks the interaction between TMPRSS2 and Spike, therefore suppress its priming and the following membrane fusion, and induces Spike to degradation.
Kun Wang, Huiqiang Wang, Shuo Wu, Ge Yang, Haiyan Yan, Lijun Qiao, Xingqiong Li, Mengyuan Wu, Jiandong Jiang, Yuhuan Li   +9 more
wiley   +1 more source

Effectiveness and safety of azvudine versus nirmatrelvir-ritonavir in adult patients infected with COVID-19 omicron strains: a retrospective study in Beijing. [PDF]

Sci Rep
The study was to evaluate the clinical outcomes of azvudine versus nirmatrelvir-ritonavir against omicron strains of coronavirus disease 2019 infections and determine their comparative effectiveness.
Xie H, Wang Y, Xu Y, Wang L, Fan J, Pan S, Shi C, Liu X, Gao X, Guo X, Yu S, Liu J, Zhang D, Yang Y, Zhang H, Wang J, Wu A, Liu X, Liu J, Zhu H, Zhou X, Tian X, Wang M.   +22 more
europepmc   +2 more sources

Additional file 1 of Effectiveness of azvudine in reducing mortality of COVID-19 patients: a systematic review and meta-analysis [PDF]

Supplementary Material 1: Supplementary Table 1. Search strategy and original results from database. Supplementary Table 2. Risk of bias of included cohort studies. Supplementary Table 3.
Luo Wang (182514), Wangji Zhou (17377042), Siqi Pan (8506767), Hong Zhang (25820), Xinlun Tian (305900), Ying Zhang (40767), Huaiya Xie (17831291), Qiaoling Chen (419924), Aohua Wu (17831294), Junping Fan (9582035), Jinglan Wang (638536), Yaqi Wang (1555240), Xueqi Liu (12882488)   +12 more
core   +1 more source